Towards a biological diagnosis of PD
- PMID: 38472075
- DOI: 10.1016/j.parkreldis.2024.106078
Towards a biological diagnosis of PD
Abstract
Since the original description by James Parkinson, Parkinson's disease (PD) has intrigued us for over 200 years. PD is a progressive condition that is incurable so far, and affects millions of people worldwide. Over the years, our knowledge has expanded tremendously, and a range of criteria have been put forward and used to try to define PD. However, owing to the complexity of the problem, it is still not consensual how to diagnose and classify a disease that manifests with diverse features, and that responds differently to existing therapies and to those under development. We are now living a time when 'biological' information is becoming abundant, precise, and accessible enabling us to attempt to incorporate different sources of information to classify different forms of PD. These refinements are essential for basic science, as they will enable us to develop improved models for studying PD, and to implement new findings into clinical practice, as this will be the path towards effective personalized medicine.
Keywords: Alpha-synuclein; Biomarker; Genetics; Neurodegeneration; Neuropathology; Parkinson's disease.
Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors have no relevant conflicts of interest to declare.
Similar articles
-
The role of neuroimaging in Parkinson's disease.J Neurochem. 2021 Nov;159(4):660-689. doi: 10.1111/jnc.15516. Epub 2021 Oct 3. J Neurochem. 2021. PMID: 34532856 Free PMC article. Review.
-
Defining the Riddle in Order to Solve It: There Is More Than One "Parkinson's Disease".Mov Disord. 2023 Jul;38(7):1127-1142. doi: 10.1002/mds.29419. Epub 2023 May 8. Mov Disord. 2023. PMID: 37156737 Review.
-
Blood-based biomarker in Parkinson's disease: potential for future applications in clinical research and practice.J Neural Transm (Vienna). 2022 Sep;129(9):1201-1217. doi: 10.1007/s00702-022-02498-1. Epub 2022 Apr 15. J Neural Transm (Vienna). 2022. PMID: 35428925 Free PMC article. Review.
-
Candidate biomarkers for Parkinson's disease.Biomed Pharmacother. 2018 Aug;104:699-704. doi: 10.1016/j.biopha.2018.05.026. Epub 2018 May 25. Biomed Pharmacother. 2018. PMID: 29803930 Review.
-
Refining the clinical diagnosis of Parkinson's disease.Parkinsonism Relat Disord. 2024 May;122:106041. doi: 10.1016/j.parkreldis.2024.106041. Epub 2024 Feb 10. Parkinsonism Relat Disord. 2024. PMID: 38360507 Free PMC article. Review.
Cited by
-
Optical coherence tomography reveals retinal structural abnormalities in α-synucleinopathies: insights from the Padua-CESNE cohort.J Neural Transm (Vienna). 2025 Jul;132(7):1013-1022. doi: 10.1007/s00702-025-02918-y. Epub 2025 Apr 15. J Neural Transm (Vienna). 2025. PMID: 40232370 Free PMC article.
-
Circadian clock dysfunction in Parkinson's disease: mechanisms, consequences, and therapeutic strategy.NPJ Parkinsons Dis. 2025 Jul 14;11(1):213. doi: 10.1038/s41531-025-01009-9. NPJ Parkinsons Dis. 2025. PMID: 40659664 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical